• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镓-68前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在鉴别寡转移和高危前列腺癌中的作用

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer.

作者信息

Erdoğan Mehmet, Özkan Emine Elif, Öztürk Sefa Alperen, Yıldız Mustafa, Şengül Sevim Süreyya

机构信息

Süleyman Demirel University Faculty of Medicine, Department of Nuclear Medicine, Isparta, Turkey

Süleyman Demirel University Faculty of Medicine, Department of Radiation Oncology, Isparta, Turkey

出版信息

Mol Imaging Radionucl Ther. 2020 Oct 19;29(3):98-104. doi: 10.4274/mirt.galenos.2020.89421.

DOI:10.4274/mirt.galenos.2020.89421
PMID:33094572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7583748/
Abstract

OBJECTIVES

In this study, we aimed to investigate whether Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scanning is adequate to predict intermediate risk, high risk, or oligometastatic prostate cancer (PCa) as an initial staging modality.

METHODS

The Ga-68 PSMA PET/CT scan images of 50 PCa patients pathologically proven by transrectal ultrasound guided biopsy were evaluated retrospectively. The association of standard uptake value maximum (SUV) value of the area with the highest PSMA expression within the primary tumor with the risk groups and metastatic burden is investigated.

RESULTS

The SUV value was 6.18 in oligometastatic patients where it was measured as 10.93 in patients with higher metastatic burden (p=0.037). The cut-off SUV value for multiple metastases was 7.96 (p=0.047). According to the regression model, SUV value has a positive influence [odds ratio (OR)=1.42], which was statistically significant (p=0.038). SUV values for intermediate and high risk patients were 6.91 and 11.44, respectively (p=0.014). The cut-off SUV value for the high risk group was 10.55 (p=0.006). In the regression model, SUV value has a positive influence (OR=1.198), which was statistically significant (p=0.021).

CONCLUSION

In this paper, we demonstrated the association between SUV value of primary tumor and Gleason score. Our results also allowed us to suggest that primary tumor SUV is a sufficiently accurate predictor of D'Amico risk groups in newly diagnosed PCa cases. Additionally, Ga-68 PSMA PET/CT turns out to be a useful tool in determining oligometastatic PCa, which requires a different treatment approach.

摘要

目的

在本研究中,我们旨在调查镓-68前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描(PSMA PET/CT)扫描作为一种初始分期方式,是否足以预测中危、高危或寡转移前列腺癌(PCa)。

方法

回顾性评估经直肠超声引导活检病理证实的50例PCa患者的镓-68 PSMA PET/CT扫描图像。研究原发肿瘤内PSMA表达最高区域的标准摄取值最大值(SUV)与风险组和转移负担之间的关联。

结果

寡转移患者的SUV值为6.18,转移负担较高的患者中该值为10.93(p=0.037)。多发转移的SUV临界值为7.96(p=0.047)。根据回归模型,SUV值具有正向影响[比值比(OR)=1.42],具有统计学意义(p=0.038)。中危和高危患者的SUV值分别为6.91和11.44(p=0.014)。高危组的SUV临界值为10.55(p=0.006)。在回归模型中,SUV值具有正向影响(OR=1.198),具有统计学意义(p=0.021)。

结论

在本文中,我们证明了原发肿瘤SUV值与Gleason评分之间的关联。我们的结果还使我们能够提出,原发肿瘤SUV是新诊断PCa病例中D'Amico风险组的一个足够准确的预测指标。此外,镓-68 PSMA PET/CT被证明是确定寡转移PCa的有用工具,而寡转移PCa需要不同的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/5679f54e7dce/MIRT-29-98-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/6349a5d628ec/MIRT-29-98-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/0394cfab6b9b/MIRT-29-98-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/5679f54e7dce/MIRT-29-98-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/6349a5d628ec/MIRT-29-98-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/0394cfab6b9b/MIRT-29-98-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/18fd/7583748/5679f54e7dce/MIRT-29-98-g3.jpg

相似文献

1
The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer.镓-68前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在鉴别寡转移和高危前列腺癌中的作用
Mol Imaging Radionucl Ther. 2020 Oct 19;29(3):98-104. doi: 10.4274/mirt.galenos.2020.89421.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
A Prospective Study on [Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.一项关于[镓]-PSMA PET/CT成像在新诊断的中高危前列腺癌中的前瞻性研究。
Asia Ocean J Nucl Med Biol. 2021 Spring;9(2):101-110. doi: 10.22038/AOJNMB.2020.52375.1358.
4
Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.[(68)Ga]PSMA-HBED-CC在前列腺癌患者中的生物分布:正常器官和肿瘤病灶摄取特征
Mol Imaging Biol. 2016 Jun;18(3):428-36. doi: 10.1007/s11307-016-0945-x.
5
Predictive value of volumetric parameters based on F-PSMA-1007 PET/CT for prostate cancer metastasis.基于F-PSMA-1007 PET/CT的体积参数对前列腺癌转移的预测价值。
Front Oncol. 2024 Feb 26;14:1335205. doi: 10.3389/fonc.2024.1335205. eCollection 2024.
6
Diagnostic performance of Gallium-PSMA-11 PET/CT to detect significant prostate cancer and comparison with FEC PET/CT.镓-PSMA-11 PET/CT检测显著前列腺癌的诊断性能及与FEC PET/CT的比较。
Oncotarget. 2017 Nov 14;8(67):111073-111083. doi: 10.18632/oncotarget.22441. eCollection 2017 Dec 19.
7
The value of F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer.F-PSMA-1007 PET/CT在识别非转移性高危前列腺癌中的价值。
EJNMMI Res. 2020 Nov 10;10(1):138. doi: 10.1186/s13550-020-00730-1.
8
Ability of Ga-PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate-risk prostate cancer: A single-center retrospective study of 147 patients.Ga-PSMA PET/CT SUVmax 区分中危前列腺癌 ISUP GG2 与 GG3 的能力:一项 147 例患者的单中心回顾性研究。
Cancer Med. 2023 Mar;12(6):7140-7148. doi: 10.1002/cam4.5516. Epub 2022 Dec 15.
9
Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描对新诊断的中高危前列腺癌的分期
Isr Med Assoc J. 2019 Feb;21(2):100-104.
10
SUVmax/ADC Ratio as a Molecular Imaging Biomarker for Diagnosis of Biopsy-Naïve Primary Prostate Cancer.SUVmax/ADC比值作为未经活检的原发性前列腺癌诊断的分子影像生物标志物
Indian J Nucl Med. 2021 Oct-Dec;36(4):377-384. doi: 10.4103/ijnm.ijnm_62_21. Epub 2021 Dec 15.

引用本文的文献

1
The Relationship between D'Amico and ISUP Risk Classifications and Ga-PSMA PET/CT SUVmax Values in Newly Diagnosed Prostate Cancers.在新发前列腺癌中,D'Amico 与 ISUP 风险分级和 Ga-PSMA PET/CT SUVmax 值之间的关系。
Curr Oncol. 2024 Sep 8;31(9):5307-5317. doi: 10.3390/curroncol31090391.
2
Characteristics of Radiopharmaceutical Uptake in Primary Tumor and Metastatic Lesions of Prostate Carcinoma: Comparison of Oligometastatic with Multimetastatic Disease.前列腺癌原发肿瘤及转移病灶中放射性药物摄取的特征:寡转移与多转移疾病的比较
Mol Imaging Radionucl Ther. 2023 Feb 23;32(1):20-27. doi: 10.4274/mirt.galenos.2022.71463.
3

本文引用的文献

1
A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?当代寡转移前列腺癌治疗的系统回顾:挑战还是风车?
World J Urol. 2019 Nov;37(11):2343-2353. doi: 10.1007/s00345-019-02652-7. Epub 2019 Jan 31.
2
Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?Ga-68-PSMA PET/CT扫描的SUVmax值能否预测具有临床意义的前列腺癌?
Nucl Med Commun. 2019 Jan;40(1):86-91. doi: 10.1097/MNM.0000000000000942.
3
Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
初发寡转移去势敏感性前列腺癌的理想联合治疗方案是什么?
World J Urol. 2023 Aug;41(8):2033-2041. doi: 10.1007/s00345-022-04239-1. Epub 2022 Dec 9.
4
Survival Outcomes After Radiotherapy for the Treatment of Synchronous Oligometastatic Prostate Cancer.同步寡转移前列腺癌放疗后的生存结果
JAMA Netw Open. 2022 Oct 3;5(10):e2235345. doi: 10.1001/jamanetworkopen.2022.35345.
5
The F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer.F-PSMA-1007 PET/CT在寡转移前列腺癌转移状态及治疗评估中的性能
Front Oncol. 2022 Aug 26;12:935979. doi: 10.3389/fonc.2022.935979. eCollection 2022.
镓-PSMA-11 PET/CT在前列腺癌初始分期中的应用:前列腺特异抗原(PSA)和 Gleason评分可预测原发肿瘤中示踪剂摄取强度。
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949. doi: 10.1007/s00259-017-3631-6. Epub 2017 Jan 31.
4
68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.68Ga-PSMA-11 动态 PET/CT 成像在原发性前列腺癌中的应用。
Clin Nucl Med. 2016 Nov;41(11):e473-e479. doi: 10.1097/RLU.0000000000001349.
5
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-ESTRO-SIOG 前列腺癌诊治指南。第 1 部分:筛查、诊断及有治愈意图的局部治疗。
Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
6
Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.(68)镓-PSMA 正电子发射断层扫描对 130 例中高危前列腺癌患者淋巴结分期的诊断效能与常规影像学比较。
J Urol. 2016 May;195(5):1436-1443. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.
7
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.2014年国际泌尿病理学会(ISUP)前列腺癌Gleason分级共识会议:分级模式的定义及新分级系统的建议
Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530.
8
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
9
The biology and treatment of oligometastatic cancer.寡转移癌的生物学特性与治疗
Oncotarget. 2015 Apr 20;6(11):8491-524. doi: 10.18632/oncotarget.3455.
10
Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.前列腺癌的分子成像:将分子生物学方法转化到临床领域
Eur Radiol. 2015 May;25(5):1294-302. doi: 10.1007/s00330-014-3539-5. Epub 2015 Feb 20.